Regulated information

2006 Financial Report

Le chiffre d’affaires s’est accru de 7,6% par rapport à l’exercice précédent.
Le résultat opérationnel courant, qui s’élève à 25,6 M€, est en augmentation de 10,8%.
Enfin, le résultat net de 15,8 M€ progresse de 27,2% et représente 7,5% du chiffre d’affaires.
Cette croissance a été maîtrisée et équilibrée.

2008 annual earnings

The Vétoquinol Board of Directors, meeting on March 20, 2009, reviewed the group’s business and approved the group’s 2008 financial statements.

2008 Interim Revenues increase by 5%

Vétoquinol generated revenues of 116.7 million euros in the first half of 2008, a 5% increase over the 111.1 million euros
reported the previous year.

2008 revenue: €234.4 M

Revenue grew in 2008, despite poor economic conditions in the second half and
an unfavourable comparison effect

2009 annual earnings

March 31, 2010 – (Lure, France) – Vétoquinol’s Board of Directors, meeting on March 11, 2010, reviewed the Group’s business and approved its 2009 financial statements.

2009 Revenue improvement in trends in the first quarter

Vétoquinol’s revenue for the first quarter of 2009 reached €57.1 M, an increase of 4.4% over the first quarter of 2008.

2010 annual earnings

Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements.

2010 Revenues grow 11.8%, driven by organic growth

The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth.

2011 annual earnings

Lure (France), April 03, 2012 – The Vétoquinol Board Meeting of March 26, 2012 has reviewed the Group’s business and approved the 2011 financial statements.

2011, a year of transition

Lure (France), January 24, 2012 – In 2011, Vétoquinol achieved sales of €284.1 million, 0.7% up on the previous year and stable on a like-for-like basis.

2012 sales up 5.0%

Lure (France), January 24, 2013 – Vétoquinol posted 2012 sales of €298.3 million, up 5.0% compared to the previous year. At constant exchange rates, annual sales increased by 3.0%.

2012, return to growth

Lure, March 26, 2013 – The Vétoquinol Board meeting of March 7, 2013 reviewed the Group's business and approved the 2012 financial statements.

2013 3rd quarter sales show organic growth

Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates.

2013 growth driven by reference products

Lure (France), March 12, 2014 – At its March 11, 2014 meeting, the Vétoquinol SA board of directors reviewed the Group results and approved the 2013 financial statements.

2014 sales up 5.2% to €315.3 million

The Vétoquinol Group posted 2014 sales of €315.3 million, up 5.2% from the previous year. At constant exchange rates, sales rose by 6.3%. The Vétoquinol Group achieved organic growth of 1.4% in 2014.

2015 results sales of reference products up 9.4% ebit up 10.3%

At its meeting on March 18, 2016, the Vetoquinol S.A. Board of Directors reviewed the Group’s results and approved the 2015 financial statements.

2015 sales up 8.7% to €342.6 million

The Vetoquinol Group posted 2015 sales of €342.6 million, up 8.7% on reported data and up 3.8% at constant exchange rates. The Group benefited from a positive currency impact of 4.9% mainly linked to the US dollar, Indian rupee and British pound.

2016 sales: €350.3 million 4.3% like-for-like growth

The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%.

2017 sales: €352.2 million 7.6% like-for-like growth in essentials products

The Vetoquinol Group posted sales of €352.2 million for the 2017 financial year, up 1.0% like-forlike. After a negative currency impact of 0.5%, mainly linked to the US and Canadian dollars, reported growth amounted to 0.5%.  

2018 sales: up 3.2% to €367.9 million

9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES

2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales)

At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

2019 sales: €396.0 million (Up 7.6%)

The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates.

2020 annual results 2020 sales: €427.5m (up 8.0% as reported)

2020 first half results consolidated sales: €196.1m (up 7.5% at constant exchange rates) net income group share: €15.1m (7.7% of sales)

At its meeting on July 29, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the first half 2020 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.”

2021 Annual results

ALL FINANCIAL INDICATORS UP.
Annual sales: €521m (up 21.9% as reported).
Essentials sales: €296m (up 34.0% as reported).
EBIT before depreciation of acquired assets: €101m (up 54.5%).
Net income - Group share: €63m (up 226.9%).

2021 first half results

2021 Half year results

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

2022 HALF YEAR RESULTS

Sales: €271m (up 6.0% as reported)
Essentials sales: €154m (up 9.8% as reported)
EBIT before depreciation of acquired assets: €52m (19.0% of sales)
Net income - Group share: €21m (7.9% of sales)
EBITDA: €62m (22.9% of sales)

2022 HALF YEAR RESULTS Additional information on the Group’s strategy

Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook.

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

3rd quarter revenues confirm promise of
strong growth prospects for 2007

For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the
corresponding period in 2006.

7.8% organic growth in Q4 2013

The Vétoquinol Group posted Q4 2013 sales of €80.1 million, up +7.8% like for like from Q4 2012.

Activity Report 2006

All key financial indicators up in 2016

At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. 

Annual earnings for 2006: a year of good performance

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

Availability of the 2019 universal registration document

Vetoquinol informs that it has filed its 2019 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 23, 2020.

Availability of the 2020 universal registration document

Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

Availability of the 2021 universal registration document

Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022.

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

BOREVE-D: Vétoquinol is participating in a project to raise awareness of the need to treat pain in cattle

June 30, 2010 (Lure, France) – Vétoquinol, in collaboration with two other veterinary laboratories, is participating in a project organised by the Syndicat de l’Industrie du Médicament Vétérinaire (SIMV) to raise awareness of the need to treat pain in cattle.

Business is strong in first-half of 2007 : + 12.9%

2007 Half year Financial Report

Buyback programs - August 2023 (french)

Monthly communication regarding buyback programs

Buyback programs - december 2022 Monthly communication regarding buyback programs

Buyback programs - december 2023

Monthly communication regarding buyback programs

Buyback programs - February 2023

Monthly communication regarding buyback programs

Buyback programs - January 2023

Monthly communication regarding buyback programs 

Buyback programs - July

Monthly communication regarding buyback programs 
 

Buyback programs - March 2024

Monthly communication regarding buyback programs

Buyback programs - november 2022

Monthly communication regarding buyback programs

Buyback programs - November 2023

Monthly communication regarding buyback programs

Buyback programs - october 2022

Monthly communication regarding buyback programs

Buyback programs - october 2023

Monthly communication regarding buyback programs

Buyback programs - september 2022

Monthly communication regarding buyback programs

Buyback programs - September 2023 (french)

Monthly communication regarding buyback programs

Buyback programs – January 2024

Monthly communication regarding buyback programs

Combined ordinary and extraordinary general meeting May 21, 2019

The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin.

Combined ordinary and extraordinary general meeting May 29, 2018

The Combined Ordinary and Extraordinary General meeting was held on Tuesday May 29, 2018 in Lure, chaired by Etienne Frechin.

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2015 (french)

Le rapport financier semestriel relatif à l’exercice 2015 peut être consulté ou téléchargé sur les sites
Internet de :
- Vétoquinol (www.vetoquinol.com)
- l’AMF (www.amf-france.org)

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2016 (french)

Communiqué de mise à disposition  du rapport financier semestriel relatif à l’exercice 2016 

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2017 (french)

Communiqué de mise à disposition  du rapport financier semestriel relatif à l’exercice 2017 

Continued sales growth driven by sustained organic growth

April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition.

Continued Sales Growth in the second Quarter of 2010

Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth.

Covid-19: Vetoquinol donates masks to neighboring healthcare facilities

Vetoquinol S.A, the animal health laboratory based in Lure (70) has decided to donate more than 6000 masks to hospitals and associations in the region. This is a civic action to help, amongst others, hospitals in the Belfort Montbéliard, Vesoul and Saint-Rémy regions.

Departure of Pierre Konareff

April 14, 2010 (Lure, France) – The Vétoquinol Group today announces the departure of Pierre
Konareff, Group Director of Finance and Legal Affairs, because of differences concerning his
position in the Group. Pierre Konareff joined Vétoquinol in July 2008.

Descriptif du programme de rachat d'actions propres soumis à l'assemblée générale à caractère ordinaire du 12 mai 2009(french)

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions qui sera soumis à l’assemblée générale à caractère ordinaire du 12 mai 2009.

Descriptif du programme de rachat d'actions propres soumis à l'assemblée générale à caractère ordinaire du 12 mai 2009(french)

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions qui sera soumis à l’assemblée générale à caractère ordinaire du 12 mai 2009.

Descriptif du programme de rachat d’actions propres soumis à l’assemblée générale à caractère ordinaire du 12 MAI 2009 (french)

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions qui sera soumis à l’assemblée générale à caractère ordinaire du 12 mai 2009.

Descriptif du programme de rachat d’actions propres soumis à l’assemblée générale mixte du 13 mai 2014

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions autorisé par l’assemblée générale mixte du 13 mai 2014.

Descriptif du programme de rachat d’actions propres soumis à
l’assemblée générale mixte du 20 mai 2011(french)

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions soumis à l’assemblée générale à caractère ordinaire du 20 mai 2011

Descriptif du programme de rachat d’actions propres soumis à l’assemblée générale mixte du 20 mai 2015 (french) Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions autorisé par l’assemblée générale mixte du 20 mai 2015.

Descriptif du programme de rachat d’actions propres soumis à l’assemblée générale mixte du 21 mai 2019 (french)

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions autorisé par l’assemblée générale mixte du 21 mai 2019.

Descriptif du programme de rachat d’actions propres soumis à l’assemblée générale mixte du 24 mai 2016 (french)

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions autorisé par l’assemblée générale mixte du  24 mai 2016. 

Descriptif du programme de rachat d’actions propres soumis à l’assemblée générale mixte du 26 mai 2020 (french)

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions autorisé par l’assemblée générale mixte du 26 mai 2020.

Descriptif du programme de rachat d’actions propres soumis à l’assemblée générale mixte du 27 mai 2021 (french)

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions autorisé par l’assemblée générale mixte du 27 mai 2021.

Descriptif du programme de rachat d’actions propres soumis à l’assemblée générale mixte du 30 mai 2017 (french)

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions autorisé par l’assemblée générale mixte du 30 mai 2017.

Descriptif du programme de rachat d’actions propres soumis à l’assemblée générale mixte du 30 mai 2017 (french)

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions autorisé par l’assemblée générale mixte du 30 mai 2017.

Descriptif du programme de rachat d’actions propres soumis à
l’assemblée générale ordinaire du 22 mai 2013

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions soumis à l’assemblée générale ordinaire du 22 mai 2013.

Descriptif du programme de rachat d’actions propres soumis à l’assemblée générale ordinaire du 7 mai 2010 (french)

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions soumis à l’assemblée générale à caractère ordinaire du 7 mai 2010.

Descriptif du programme de rachat d’actions propres soumis àl’assemblée générale ordinaire du 24 mai 2012

Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions soumis à l’assemblée générale ordinaire du 24 mai 2012.

Descriptif du programme de rachat par la société de ses propres actions autorisé par l'assemblée générale mixte des actionnaires du 9 octobre 2006 et mis en œuvre par le conseil d'administration du 8 décembre 2006 (french)

Dominique Derveaux appointed Group Chief Operations Officer Effective April 1, 2020, Vetoquinol’s Board of Directors has appointed Dominique Derveaux Group Chief Operations Officer. In this capacity, he will run the Business, Marketing & Medical, Industrial, and Information Systems departments. He will report to Vetoquinol CEO Matthieu Frechin.

Double-digit growth in 2021

Total Group Sales: €521 million (up 21.9% as reported)
Annual Sale of Essential products: €296 million (up 34.0% as reported)

Dynamic first half 2016

2016 Half year Financial Report

Earnings for 2007 attest to strength of business growth model

The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance
indicators, ahead of its medium-term targets. According to the most recent statistics published by Vetnosis, this substantial rise in revenue has lifted Vétoquinol to third place
worldwide.

European launch of new Nsaid Cimalgex®

Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs.

First half 2015 sales €167.2m, up 11.9%

The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements.

First half 2018 results

At its meeting on July 25, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2018 financial statements.

First half 2019 results

At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements.

First nine months 2022 sales: €405M

In line with year-end outlook

Flevox® the new parasiticide for dogs and cats

Lure (France), 14 February 2012 – Vétoquinol launches Flevox®, the latest addition to its range of parasiticides. The new drug is based on fipronil, the molecule par excellence in the treatment of tick and flea infestations in pets.

Forcyl® - a booming brand

Lure (France), November 14, 2012 – Vétoquinol receives a new indication for its Forcyl® product, designed for cattle, and a new market authorization for Forcyl® Swine for pigs.

Forcyl®: european launch of new drug

Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection.

Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%)

At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements.

Growth in Revenues in the first half of 2009

Vétoquinol’s revenues in the first half of 2009 totalled EUR 119.9 million, an increase of 2.7% compared to the first half of the preceding year.

H1 2022 Sales

H1 2022 Sales: €271m, up 6.1%
+2.0% on a like-for-like basis
H1 2022 Essentials Sales: €154m, up 9.8%
+6.8% on a like-for-like basis